10-Q: Alpha Teknova Narrows Losses, Boosts Gross Profit in Q3 2025

Alpha Teknova reported significantly reduced net losses and a substantial increase in gross profit for the third quarter and first nine months of 2025, driven by revenue growth and improved manufacturing efficiency.

Summary

• Net loss for Q3 2025 significantly decreased to $4.3 million from $7.6 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, improved to $12.5 million from $21.0 million in the prior year period.
• Total revenue for Q3 2025 increased by 9.2% to $10.5 million, with Lab Essentials growing 16.0% to $8.3 million.
• Total revenue for the nine months ended September 30, 2025, grew by 7.2% to $30.5 million, with Lab Essentials up 9.8% to $24.2 million.
• Gross profit for Q3 2025 surged to $3.2 million (30.7% gross margin) from $0.1 million (0.9% gross margin) in Q3 2024, primarily due to the absence of $2.8 million in non-recurring inventory charges from the prior year.
• Excluding non-recurring charges, the gross profit percentage improved from 29.8% in Q3 2024 to 30.7% in Q3 2025, and from 27.6% to 33.4% for the nine-month period, driven by manufacturing efficiency gains and higher revenue.
• Operating expenses decreased by 4.0% in Q3 2025 and 11.9% for the nine-month period, largely due to reduced general and administrative expenses and lower R&D costs.
• Cash used in operating activities significantly decreased to $8.2 million for the nine months ended September 30, 2025, from $11.5 million in the prior year.
• The company refinanced its credit agreement on March 3, 2025, securing a $28.245 million facility, including a $23.245 million term loan and a $5.0 million revolver.
• A shelf registration statement on Form S-3 was filed on July 10, 2025, allowing for future offerings of up to $225 million in securities.

Sentiment

Score: 7

Explanation: The company demonstrated significant improvements in reducing net losses and increasing gross profit, driven by revenue growth and cost management. The successful refinancing of debt and the establishment of a shelf registration statement provide financial flexibility and stability. However, the company remains unprofitable and faces ongoing macroeconomic risks and competition.

Positives

• Significant reduction in net loss for both the three-month ($4.3 million vs $7.6 million) and nine-month ($12.5 million vs $21.0 million) periods ended September 30, 2025, compared to 2024.
• Strong revenue growth of 9.2% for Q3 2025 and 7.2% for the nine months ended September 30, 2025.
• Gross profit percentage improved to 30.7% in Q3 2025 (from 0.9% in Q3 2024, or 29.8% excluding non-recurring charges) and to 33.4% for the nine months (from 17.9% in 9M 2024, or 27.6% excluding non-recurring charges), indicating better operational efficiency.
• Operating expenses decreased by 4.0% in Q3 2025 and 11.9% for the nine months, reflecting cost management efforts, particularly in general and administrative expenses.
• Net cash used in operating activities improved significantly, decreasing from $11.5 million in 9M 2024 to $8.2 million in 9M 2025.
• Net cash provided by investing activities turned positive at $7.5 million for 9M 2025, compared to cash used of $25.9 million in 9M 2024, primarily due to maturities of short-term investments.
• Successful refinancing of the credit agreement provides a $28.245 million facility, extending maturity to March 1, 2030, and delaying principal repayments until April 1, 2028.
• Lab Essentials product category showed robust growth of 16.0% in Q3 2025 and 9.8% for the nine months, driven by higher average revenue per customer and an increased customer base.

Negatives

• Clinical Solutions revenue decreased by 13.1% in Q3 2025 and 6.1% for the nine months, primarily due to lower average revenue per customer.
• The company continues to incur net losses, with a net loss of $4.3 million in Q3 2025 and $12.5 million for the nine months ended September 30, 2025.
• Cash and cash equivalents decreased from $3.7 million at December 31, 2024, to $3.2 million at September 30, 2025.
• Total current assets decreased from $42.8 million at December 31, 2024, to $36.6 million at September 30, 2025.
• Total stockholders' equity decreased from $82.4 million at December 31, 2024, to $72.7 million at September 30, 2025.
• Net cash provided by financing activities significantly decreased from $15.0 million in 9M 2024 to $0.2 million in 9M 2025, indicating less reliance on new equity financing in the current period.

Risks

• General economic, market, or business conditions, including inflation and interest rate changes, may impact customer demand and increase operating costs.
• Inability to meet publicly announced guidance or other expectations about the business.
• Uncertainty regarding the ability to grow profitability and achieve or maintain profitability in the future, given a recent history of losses.
• Reliance on a limited number of suppliers for certain raw materials without long-term supply arrangements.
• Potential for increased competition from new market entrants and more advanced technologies.
• Challenges in hiring and retaining key personnel.
• Difficulty in obtaining capital on favorable terms, or at all.
• Sensitivity of customers to product nonconformances, defects, and errors.
• Inability to secure and maintain a stable supply of raw materials.
• Market price of common stock could drop significantly due to sales of a substantial number of shares by existing holders, particularly affiliates, or the perception of such sales.
• Future issuance of securities in connection with investments or acquisitions could result in additional dilution to shareholders.
• Impact of any pandemic, epidemic, natural disasters, geopolitical unrest (including in Ukraine and the Israeli-Hamas war), terrorism, or public health issues on business operations.

Future Outlook

The company expects operating expenses to increase in future periods as it attracts and retains qualified personnel, invests in processes and infrastructure to improve operating efficiency and expand capacity (including new manufacturing, warehouse, and distribution facilities), and builds its brand and market presence. It is closely monitoring economic uncertainty, including inflation, interest rates, and changes to tariff and trade policy, which may negatively impact business by increasing costs or reducing customer demand. The company aims to generate future revenue growth in market segments such as molecular diagnostics, synthetic biology, and emerging therapeutic modalities.

Management Comments

• "While our expenses may fluctuate over the short term, we expect our expenses will increase in future periods, in connection with our ongoing activities as we: attract, hire, and retain qualified personnel; invest in processes and infrastructure to improve operating efficiency and expand capacity at our facilities, including the ramp up of our new, state-of-the-art manufacturing, warehouse, and distribution facilities; and build our brand and market and sell our products and services."
• "We are closely monitoring economic uncertainty in the U.S. and abroad."
• "We cannot predict the impact of future inflation and interest rate changes on the results of our operations."

Industry Context

Alpha Teknova operates in the life sciences market, providing critical reagents for discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. The company's ISO 13485:2016 certification positions it to serve diagnostic and therapeutic applications, supporting customers from early research through commercialization. The broader industry faces economic uncertainties, including inflation and interest rate fluctuations, which could impact customer spending and operational costs. The company's focus on custom, made-to-order products with short turnaround times and scalability aligns with industry needs for flexible and high-quality supply chains.

Legal Proceedings

• A former employee filed a claim in August 2023 with the California Labor and Workforce Development Agency alleging violations of California's labor, wage, and hour laws.
• The company agreed to settle the claims for $0.4 million during a mediation on June 6, 2024.
• The settlement received final court approval in April 2025, and the company paid the settlement amount.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings under the shelf registration statement. Improved financial performance (reduced losses, increased gross profit) could positively impact investor confidence. However, sales of a substantial number of shares by affiliates could reduce market price.
• Employees: Reduction in workforce of approximately 35 positions in January 2024. Stock option repricing in March 2024 aimed to benefit eligible employees. Future plans include attracting, hiring, and retaining qualified personnel.
• Customers: Continued focus on providing critical reagents and custom, made-to-order products with short turnaround times. Potential impact from economic uncertainty causing reduced, delayed, or canceled orders.
• Suppliers: Reliance on a limited number of suppliers for certain raw materials without long-term supply arrangements poses a risk.
• Creditors: Refinancing of credit agreement with MidCap Financial Trust provides a stable debt structure with extended maturity and delayed principal repayments. Minimum net revenue and cash requirements are conditions of the debt.

Next Steps

• Continue to attract, hire, and retain qualified personnel.
• Invest in processes and infrastructure to improve operating efficiency and expand capacity, including the ramp-up of new manufacturing, warehouse, and distribution facilities.
• Build the company's brand and market and sell its products and services.
• Monitor general economic, market, or business conditions, including inflation and interest rate changes.
• Pursue potential acquisitions that further or accelerate the company's strategy (if additional $10.0 million tranche of term loan becomes available).
• Potentially utilize the $225 million shelf registration for future equity or debt financings to execute business strategy.
• Begin principal repayments on the Second Amended and Restated Credit Agreement on April 1, 2028.

Key Dates

Recommendation

While the company has shown significant improvements in reducing net losses and increasing gross profit, it remains unprofitable. The revenue growth is positive, particularly in Lab Essentials, and cost management efforts are evident. The debt refinancing provides stability, and the shelf registration offers future capital flexibility. However, the company still faces macroeconomic headwinds, customer concentration risks, and the potential for dilution from future capital raises. The stock option repricing also indicates past challenges with employee incentives. Given the mixed signals of improving operational efficiency but continued unprofitability and external risks, a "hold" recommendation is appropriate for a seasoned investor to observe sustained profitability and execution of growth strategies.

Keywords

Life sciences, Biotechnology, Pharmaceutical, Molecular diagnostics, Reagents, Cell culture media, Lab Essentials, Clinical Solutions, SEC filing, 10-Q, Financial results, Earnings, Gross profit, Net loss, Operating expenses, Debt financing, Capital raise, Stock options, Teknova